Publications by authors named "Ze-Lin Zhan"

Claim this Profile
L
Letter to the Editor regarding the article "SGLT2 inhibitors and cardiovascular and renal outcomes: a meta‑analysis and trial sequential analysis".
Mei Qiu, Liang-Liang Ding, Ze-Lin Zhan, Hai-Rong Zhou

Heart Fail Rev· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comprehensive Analysis of Adverse Events Associated With SGLT2is: A Meta-Analysis Involving Nine Large Randomized Trials.
Mei Qiu, Li-Min Zhao, Ze-Lin Zhan

Front Endocrinol (Lausanne)· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Network Meta-Analysis on the Effects of SGLT2 Inhibitors Versus Finerenone on Cardiorenal Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease.
Li-Min Zhao, Ze-Lin Zhan, Jie Ning, Mei Qiu

Front Pharmacol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Commentary: Sodium Glucose Cotransporter 2 Inhibitors Reduce the Risk of Heart Failure Hospitalization in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Mei Qiu, Liang-Liang Ding, Ze-Lin Zhan, Hai-Rong Zhou

Front Endocrinol (Lausanne)· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sotagliflozin Reduces HF Events in T2DM Regardless of Baseline Characteristics, Including HF, CKD and LVEF.
Li-Min Zhao, Liang-Liang Ding, Ze-Lin Zhan, Mei Qiu

Cardiovasc Drugs Ther· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gliflozins for the prevention of stroke in diabetes and cardiorenal diseases: A meta-analysis of cardiovascular outcome trials.
Li-Min Zhao, Jia-Nan Huang, Mei Qiu, Liang-Liang Ding, Ze-Lin Zhan

Medicine (Baltimore)· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of SGLT2 inhibitors on cardiovascular death and all-cause death in patients with type 2 diabetes and chronic kidney disease: an updated meta-analysis including the SCORED trial.
Li-Min Zhao, Ze-Lin Zhan, Mei Qiu

Ther Adv Endocrinol Metab· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of SGLT2 inhibitors and occurrence of noninfectious respiratory disorders: a meta-analysis of large randomized trials of SGLT2 inhibitors.
Mei Qiu, Liang-Liang Ding, Ze-Lin Zhan, Shu-Yan Liu

Endocrine· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Do all gliflozins reduce stroke in patients with type 2 diabetes mellitus and impaired renal function?
Li-Min Zhao, Liang-Liang Ding, Ze-Lin Zhan, Mei Qiu

J Stroke Cerebrovasc Dis· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Meta-Analysis on the Safety and Cardiorenal Efficacy of SGLT2 Inhibitors in Patients Without T2DM.
Lu-Feng Li, Liang-Liang Ding, Ze-Lin Zhan, Mei Qiu

Front Cardiovasc Med· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Do four SGLT2 inhibitors lead to different cardiorenal benefits in type 2 diabetes, in chronic heart failure, and in chronic kidney disease?
Mei Qiu, Liang-Liang Ding, Ze-Lin Zhan, Hai-Rong Zhou

Eur J Intern Med· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SGLT2 inhibitors should be recommended in patients with one or more of the three diseases: type 2 diabetes, chronic kidney disease, and HFrEF.
Li-Min Zhao, Liang-Liang Ding, Ze-Lin Zhan, Mei Qiu

Eur J Intern Med· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Does Combination Therapy With SGLT2 Inhibitors and Renin-Angiotensin System Blockers Lead to Greater Reduction in Cardiorenal Events Among Patients With Type 2 Diabetes?
Li-Min Zhao, Miao Zhang, Ze-Lin Zhan, Mei Qiu

Front Cardiovasc Med· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Meta-analysis of the effects of four factors on the efficacy of SGLT2 inhibitors in patients with HFrEF.
Mei Qiu, Liang-Liang Ding, Ze-Lin Zhan, Hai-Rong Zhou

ESC Heart Fail· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis